Aktis OncologyAKTS -1.90%9 PB Ratio is 3.04 as of Jul. 12, 2026, which is 37% above its 10-year median of 2.22. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 1,231 Biotechnology companies, Aktis Oncology ranks worse than 51.1% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-12), Aktis Oncology's share price is $27.88. Aktis Oncology's Book Value per Share for the quarter that ended in Mar. 2026 was $9.16. Hence, Aktis Oncology's PB Ratio of today is 3.04.
The historical rank and industry rank for Aktis Oncology's PB Ratio or its related term are showing as below:
AKTS'
s PB Ratio Range Over the Past 10 Years
Min: 1.84 Med: 2.22 Max: 3.47
Current: 3.04
During the past 4 years, Aktis Oncology's highest PB Ratio was 3.47. The lowest was 1.84. And the median was 2.22.
AKTS's PB Ratio is ranked worse than 51.1% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs AKTS: 3.04
During the past 3 years, the average Book Value Per Share Growth Rate was -96.60% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Aktis Oncology was -96.60% per year. The lowest was -96.60% per year. And the median was -96.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Aktis Oncology PB Ratio Related Terms
Aktis Oncology PB Ratio Historical Data
* Premium members only.
The historical data trend for Aktis Oncology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aktis Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aktis Oncology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aktis Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aktis Oncology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Aktis Oncology's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Aktis Oncology (AKTS) has a PB Ratio of 3.04 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aktis Oncology and its competitors. This is 37% above median its historical median of 2.22. Over the past decade, Aktis Oncology's PB Ratio has ranged from 1.84 to 3.47. According to the industry distribution chart, Aktis Oncology ranks #629 out of 1231 companies in the Biotechnology industry, placing it in the top 51.1%.
Is Aktis Oncology's PB Ratio too high?
Aktis Oncology's current PB Ratio of 3.04 is 37% above median its 10-year median of 2.22. Over the past 10 years, this metric has ranged from a low of 1.84 to a high of 3.47. The Biotechnology industry median PB Ratio is 2.93. Aktis Oncology's value of 3.04 is 3.8% above this industry median. Based on the distribution chart, Aktis Oncology ranks #629 out of 1231 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's PB Ratio compare to ZBIO and MLTX?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #629 out of 1231 companies for PB Ratio. This places Aktis Oncology in the lower half of its industry. The industry median PB Ratio is 2.93. Aktis Oncology's value of 3.04 is 3.8% above this benchmark. Historically, Aktis Oncology's own PB Ratio has ranged from 1.84 to 3.47 over the past decade. While the company's 10-year median is 2.22 vs. the industry median of 2.93, Aktis Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aktis Oncology's current PB Ratio of 3.04 is 3.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aktis Oncology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aktis Oncology's current PB Ratio is 3.04, which is 37% above median its own 10-year median of 2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current PB Ratio of 3.04. The current PB Ratio is 3.04, which is 37% above median its 10-year median of 2.22 and 3.8% above the Biotechnology industry median of 2.93. Aktis Oncology's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current PB Ratio is 3.04 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score
Get the complete analysis for AKTS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTS has been successfully added to your 